RIGEL PHARMACEUTICALS INC (RIGL) Stock Overview
NASDAQ:RIGL - US7665597024 - Common Stock
RIGL Key Statistics, Chart & Performance
The current stock price of RIGL is 40.74 USD. In the past month the price increased by 103.8%. In the past year, price increased by 203.13%.
RIGL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.6 | 366.65B | ||
| AMGN | AMGEN INC | 13.23 | 155.30B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 141.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.96 | 99.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.54 | 60.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.15B | ||
| ARGX | ARGENX SE - ADR | 73.07 | 41.45B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.25 | 36.69B | ||
| INSM | INSMED INC | N/A | 27.12B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.26B | ||
| NTRA | NATERA INC | N/A | 22.30B | ||
| BIIB | BIOGEN INC | 8.52 | 19.99B |
Related stock screener links
About RIGL
Company Profile
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 162 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. The company is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Company Info
RIGEL PHARMACEUTICALS INC
611 Gateway Boulevard, Suite 900
South San Francisco CALIFORNIA 94080 US
CEO: Raul R. Rodriguez
Employees: 162
Phone: 16506241100
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the stock price of RIGEL PHARMACEUTICALS INC today?
The current stock price of RIGL is 40.74 USD. The price decreased by -1.83% in the last trading session.
What is the ticker symbol for RIGEL PHARMACEUTICALS INC stock?
The exchange symbol of RIGEL PHARMACEUTICALS INC is RIGL and it is listed on the Nasdaq exchange.
On which exchange is RIGL stock listed?
RIGL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RIGEL PHARMACEUTICALS INC stock?
12 analysts have analysed RIGL and the average price target is 39.1 USD. This implies a price decrease of -4.03% is expected in the next year compared to the current price of 40.74. Check the RIGEL PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RIGEL PHARMACEUTICALS INC worth?
RIGEL PHARMACEUTICALS INC (RIGL) has a market capitalization of 730.88M USD. This makes RIGL a Small Cap stock.
How many employees does RIGEL PHARMACEUTICALS INC have?
RIGEL PHARMACEUTICALS INC (RIGL) currently has 162 employees.
What are the support and resistance levels for RIGEL PHARMACEUTICALS INC (RIGL) stock?
RIGEL PHARMACEUTICALS INC (RIGL) has a support level at 18.95. Check the full technical report for a detailed analysis of RIGL support and resistance levels.
Is RIGEL PHARMACEUTICALS INC (RIGL) expected to grow?
The Revenue of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 62.09% in the next year. Check the estimates tab for more information on the RIGL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy RIGEL PHARMACEUTICALS INC (RIGL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RIGL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RIGL, evaluating the profitability, health, valuation and growth aspects
- RIGEL PHARMACEUTICALS INC (RIGL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RIGEL PHARMACEUTICALS INC (RIGL) Sales and EPS estimates to see what analysts future expectations are.
- RIGEL PHARMACEUTICALS INC (RIGL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RIGEL PHARMACEUTICALS INC (RIGL) Insider and Institutional Ownership to learn about the owners and their transactions.
- RIGEL PHARMACEUTICALS INC (RIGL) Stock Chart to make your own analysis
- RIGEL PHARMACEUTICALS INC (RIGL) Latest news and press-releases to stay up to date.
Does RIGEL PHARMACEUTICALS INC (RIGL) stock pay dividends?
RIGL does not pay a dividend.
When does RIGEL PHARMACEUTICALS INC (RIGL) report earnings?
RIGEL PHARMACEUTICALS INC (RIGL) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of RIGEL PHARMACEUTICALS INC (RIGL)?
The PE ratio for RIGEL PHARMACEUTICALS INC (RIGL) is 7.53. This is based on the reported non-GAAP earnings per share of 5.41 and the current share price of 40.74 USD. Check the full fundamental report for a full analysis of the valuation metrics for RIGL.
What is the Short Interest ratio of RIGEL PHARMACEUTICALS INC (RIGL) stock?
The outstanding short interest for RIGEL PHARMACEUTICALS INC (RIGL) is 14.43% of its float. Check the ownership tab for more information on the RIGL short interest.
RIGL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RIGL. When comparing the yearly performance of all stocks, RIGL is one of the better performing stocks in the market, outperforming 98.33% of all stocks.
RIGL Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RIGL. Both the profitability and the financial health of RIGL get a neutral evaluation. Nothing too spectacular is happening here.
RIGL Financial Highlights
Over the last trailing twelve months RIGL reported a non-GAAP Earnings per Share(EPS) of 5.41. The EPS increased by 729.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 36.51% | ||
| ROA | 47.32% | ||
| ROE | 119.39% | ||
| Debt/Equity | 0.46 |
RIGL Forecast & Estimates
12 analysts have analysed RIGL and the average price target is 39.1 USD. This implies a price decrease of -4.03% is expected in the next year compared to the current price of 40.74.
For the next year, analysts expect an EPS growth of 503.1% and a revenue growth 62.09% for RIGL